Confirmation of administrative claims-identified opportunistic infections and other serious potential adverse events associated with tumor necrosis factor α antagonists and disease-modifying antirheumatic drugs

Arthritis Care and Research

Volumn 57, Issue 2, 2007, Pages 343-346

  Curtis, J R ^a   Martin, C ^b   Saag, K G ^a   Patkar, N M ^a   Kramer, J ^c   Shatin, D ^b   Allison, J ^a   Braun, M M ^d  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b Center for Health Care Policy and Evaluation   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ADULT; APLASTIC ANEMIA; ARTICLE; BILLING AND CLAIMS; COCCIDIOIDOMYCOSIS; CROHN DISEASE; CRYPTOCOCCOSIS; FEMALE; HEALTH CARE ORGANIZATION; HISTOPLASMOSIS; HUMAN; INCIDENCE; LUPUS LIKE SYNDROME; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; PNEUMOCYSTOSIS; RHEUMATOID ARTHRITIS; TUBERCULOSIS; DRUG ANTAGONISM; FACTUAL DATABASE; HEALTH INSURANCE; MIDDLE AGED; PREDICTION AND FORECASTING; STATISTICS;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CROHN DISEASE; DATABASES, FACTUAL; FEMALE; HUMANS; IMMUNOGLOBULIN G; INCIDENCE; INSURANCE, HEALTH; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; PREDICTIVE VALUE OF TESTS; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34547445090     PISSN: 21514658     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.22544     Document Type: Article

References (13)

1. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. New Engl J Med 2001;345:1098-104.
2. Bergstrom L, Yocum DE, Ampel NM, Villanueva I, Lisse J, Gluck O, et al. Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor α antagonists. Arthritis Rheum 2004;50:1959-66.
3. Seddik M, Meliez H, Seguy D, Viget N, Cortot A, Colombel JF. Pneumocystis jiroveci (carinii) pneumonia following initiation of infliximab and azathioprine therapy in a patient with Crohn's disease [published erratum in Inflamm Bowel Dis 2005;11:705]. Inflamm Bowel Dis 2004;10:436-7.
4. Velayos FS, Sandborn WJ. Pneumocystis carinii pneumonia during maintenance anti-tumor necrosis factor-α therapy with infliximab for Crohn's disease. Inflamm Bowel Dis 2004;10: 657-60.
5. Shatin D, Rawson N, Stergachis A. UnitedHealthGroup. In: Strom B, editor. Pharmacoepidemiology. 4th ed. West Sussex: John Wiley & Sons; 2005.
6. Kiyota Y, Schneeweiss S, Glynn RJ, Cannuscio CC, Avorn J, Solomon DH. Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J 2004;148:99-104.
7. West S, Strom B, Poole C. Validity of pharmacoepidemiologic drug and diagnosis data. In: Strom BL, editor. Pharmacoepidemiology. 4th ed. West Sussex: John Wiley & Sons; 2005.
8. Choquette D, Einarson T, Leombruno J. Opportunistic infections with anti-TNF agents: estimating incidence from pharmacy and physician claims databases. Arthritis Rheum 2005; 52:S349-50.
9. Smitten A, Simon T, Hochberg M, Suissa S. Rates of infection in rheumatoid arthritis [abstract]. Arthritis Rheum 2004;50: S478-9.
10. Metlay J, Kinman J. Failure to validate pneumococcal pneumonia diagnoses in the general practice research database [abstract]. Pharmacoepidemiol Drug Saf 2003;12:S163-4.
11. Leveille SG, Gray S, Black DJ, LaCroix AZ, Ferrucci L, Volpato S, et al. A new method for identifying antibiotic-treated infections using automated pharmacy records. J Clin Epidemiol 2000;53:1069-75.
12. Sands K, Vineyard G, Livingston J, Christiansen C, Platt R. Efficient identification of postdischarge surgical site infections: use of automated pharmacy dispensing information, administrative data, and medical record information. J Infect Dis 1999;179:434-41.
13. Yokoe DS, Coon SW, Dokholyan R, Iannuzzi MC, Jones TF, Meredith S, et al. Pharmacy data for tuberculosis surveillance and assessment of patient management. Emerg Infect Dis 2004;10:1426-31.